28,648 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 28,648 shares of the company’s stock, valued at approximately $773,000.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Mineralys Therapeutics during the 2nd quarter worth about $158,832,000. State Street Corp raised its position in shares of Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after acquiring an additional 1,881,976 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Mineralys Therapeutics by 6,097.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after acquiring an additional 1,303,737 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Mineralys Therapeutics by 6,012.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock worth $44,005,000 after acquiring an additional 1,193,417 shares during the last quarter. Finally, RA Capital Management L.P. grew its holdings in Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after purchasing an additional 1,176,470 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Stock Performance

MLYS opened at $28.21 on Monday. The stock has a market capitalization of $2.49 billion, a P/E ratio of -6.65 and a beta of 0.68. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18. Mineralys Therapeutics, Inc. has a 12 month low of $22.30 and a 12 month high of $47.65. The firm’s fifty day simple moving average is $27.02 and its 200 day simple moving average is $27.09.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). As a group, research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Zacks Research lowered Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Mineralys Therapeutics presently has an average rating of “Hold” and a consensus target price of $49.33.

Insider Transactions at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 75,000 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the completion of the transaction, the chief executive officer directly owned 614,321 shares in the company, valued at approximately $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Rodman sold 9,890 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $23.81, for a total value of $235,480.90. Following the completion of the sale, the insider directly owned 57,095 shares in the company, valued at approximately $1,359,431.95. This represents a 14.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 224,333 shares of company stock valued at $5,806,213 over the last three months. 18.94% of the stock is currently owned by corporate insiders.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.